AzTrials
AzTrials

OligohydramniosNCT03935607

The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index

An observational study of Oligohydramnios, run by Rambam Health Care Campus at 1 site in Israel.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Oligohydramnios
What is being tested?
Transvaginal sonography
How many people
350 participants
Where
1 siteIsrael
Study dates
1 Jul 2019to 1 Apr 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Adult

Study population: Women who meet the above inclusion criteria will be asked to participate in the study and to provide a written informed consent. This study, under no circumstances, will alter the participants routine care.

Who may be able to join

  • Pregnant women at term beyond 37 weeks' gestation
  • Presented to our hospital for their routine care or prior to induction of labor
  • Singleton pregnancy
  • Planned for vaginal delivery
  • Non-laboring women with non-engaged fetal presenting part

Who cannot join

  • Pregnant women under 37 weeks' gestation
  • Planned cesarean deliveries
  • Laboring women with engaged fetal presenting part
  • Multiple gestation

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Rambam health care campus

    Haifa

Other trials in Israel

About this study

Official title: The Pseudo-Oligohydramnios/Hidden Pocket Study: The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index

The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. After obtaining informed consent, transvaginal sonography will be used to evaluate and measure a possible amniotic fluid pocket that may precede the fetal presenting part.

Read the detailed description

Background Normal amniotic fluid volume varies across gestation (Ounpraseuth 2017). Abnormal amniotic fluid volume has been associated with a variety of adverse pregnancy outcomes (Shrem 2016). In clinical practice, the amniotic fluid volume is a component of the biophysical profile which provides information on fetal well-being.

Transabdominal ultrasound is used to assess quantitatively the amniotic fluid volume, most commonly by either the Amniotic Fluid Index (AFI) or the Maximum Vertical Pocket (MVP) methods.

The value of the AFI method has been questioned in several studies, which have shown that an abnormal test, low or high, is neither highly accurate nor predictive of adverse outcome. Many pregnancies with normal AFI will be falsely characterized as abnormal, and a large number with truly abnormal AFI will be missed (Magann 1994, Chauhan 1997).

The MVP measurement may be preferred over the AFI method. A 2008 systematic review of randomized trials found that use of the AFI increased the rate of diagnosis of oligohydramnios (RR 2.3), induction of labor (RR 2.1), and cesarean delivery for fetal distress (RR 1.5) (Nabhan 2008).

Rationale and Hypothesis of the Study Recently, our group observed that when transvaginal ultrasound is being performed to non-laboring pregnant women at term for other obstetrical indications, there is a large amniotic fluid pocket above the internal cervical os and below the fetal presenting part. Due to the unique location of this pocket, we hypothesized that transvaginal ultrasound may provide better information than transabdominal ultrasound on amniotic fluid volume, particularly in cases when suspecting abnormal low amniotic fluid volume.

Data Collection

  1. Maternal and fetal characteristics Data related to the fetomaternal antenatal, intrapartum and postpartum course will be recorded prospectively.
  2. Ultrasound assessment Each eligible woman in the study population group will be asked to undergo prenatal ultrasound examination twice. The first ultrasound examination is a routine transabdominal ultrasound examination that is carried out to assess fetal growth and well-being. This is to be continued with a second transvaginal ultrasound, with a specific focus on the amniotic fluid pocket, that is; the distance in centimetres between the fetal presenting part and the internal cervical os. The second transvaginal ultrasound will be performed for the purpose of the study only, and by one other research team member that is blinded to the first routine transabdominal ultrasound. The entire length of the study, combining the transabdominal and transvaginal ultrasounds, is expected to take on the average around 15 min.

Ultrasound Equipment and Safety Considerations In their 2011 statement, The International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) and World Federation of Ultrasound in Medicine and Biology (WFUMB) consider ultrasonography to be safe for use during clinical practice (ISUOG 2011).

Statistical analyses and sample size For sample size calculation, and given a 20% rate of induction of labor, of which 3% are due to abnormal low amniotic fluid volume (oligohydramnios), a sample size of 1000 women is required.

Feasibility of the Study Considering the high volume of maternal care here at Rambam Health Care Campus, and that every year there are around 5,000 births and nearly double routine cares, the recruitment process for the current study is feasible.

Expected Duration of the Study The recruitment for the study is expected to take place over 12 months with an additional 3-6 months after recruitment for data analysis before publication.

Funding Women will be recruited while approaching Rambam Health Care Campus for their routine obstetric care. Ultrasound examinations will be carried out using existing operational ultrasound equipments within the obstetric department at Rambam Health Care Campus. For both, the recruitment and the ultrasound examinations, no extra funding is currently required.

Public Health Interest Identifying new ultrasound variables that can assist in quantifying amniotic fluid volume, as the one suggested in the current study, is of great importance and may provide invaluable information into the overall future care and decision-making around the time of delivery, especially whether or not to induce labor in women with suspected oligohydramnios. Thus, it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.

Conditions
Oligohydramnios
Being tested
Transvaginal sonography
Medical subject headings
Oligohydramnios

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transvaginal sonographyDiagnostic test

    Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.

Study groups in NCT03935607
Study groupRoleWhat they receive
Normal amniotic fluid indexPatients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
Receives: Diagnostic Test: Transvaginal sonography
OligohydramniosPatients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
Receives: Diagnostic Test: Transvaginal sonography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Amniotic Fluid Fore-Pocket

    Measurement of amniotic fluid pocket preceding fetal presenting part.

    Measured: Up to 30 minutes from the beginning of patient evaluation.

Secondary outcomes (5)
  1. Mode of delivery

    Vaginal delivery, vacuum assisted delivery, cesarean section.

    Measured: From time of induction up to 48 hours postpartum

  2. pH level

    Umbilical artery pH level

    Measured: From the time of delivery up to 30 days postpartum

  3. 1 minute Apgar score

    Neonatal 1st minute Apgar score

    Measured: From the time of delivery up to 30 days postpartum

  4. 5 minute Apgar score

    Neonatal 5th minute Apgar score

    Measured: From the time of delivery up to 30 days postpartum

  5. Neonatal intensive care unit admission

    Rate of neonatal intensive care unit admission

    Measured: From the time of delivery up to 30 days postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2019
  2. Study start1 Jul 2019
  3. Primary completion31 Dec 2021
  4. Study completion1 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
350 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03935607
Sponsor's protocol ID
0017-19-RMB
Status last verified
Apr 2022
First submitted
25 Apr 2019
Last updated
20 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Oligohydramnios, run by Rambam Health Care Campus at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Amniotic Fluid Fore-Pocket (time frame: Up to 30 minutes from the beginning of patient evaluation.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in